ArticleScientific reports2026
A distributed fusion framework for breast cancer recurrence prediction using MapReduce.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer recurrence remains a major clinical challenge, significantly influencing long-term survival and treatment planning. Accurate early prediction is hindered by heterogeneous clinical factors, imbalanced datasets, and the distributed nature of medical records stored across hospitals, registries, and laboratories. To address these challenges, this study proposes a MapReduce-aligned hybrid framework that combine with distributed Spark-based Gradient Boosted Trees, denoising autoencoder (AE)-derived latent representations, calibrated XGBoost, and deep tabular framework (FT-Transformer and TabTransformer). The framework is designed to operate efficiently on heterogeneous, large-scale datasets while preserving data locality. Two benchmark datasets; the SEER breast cancer recurrence cohort and the Wisconsin Diagnostic Breast Cancer dataset were used to evaluate framework performance across clinical data. Experimental results show that the proposed calibrated XGBoost and AE-augmented fusion frameworks obtained superior discrimination, calibration with the Wisconsin dataset reaching ROC-AUC values of 0.9954 and MCC ≥ 0.981. On the SEER dataset, characterized by high heterogeneity and sparse recurrence signals, the fusion framework attained improved recall, while calibrated XGBoost offered the best overall balance between precision and stability. The findings demonstrate that combining tree-based embedded feature selection, latent AE compression, and transformer-based contextual frameworking yields consistent performance gains. Moreover, the Spark-GBT integration ensures scalability and suitability for multi-institutional environments where data centralization is restricted. The experimental results show that the proposed fusion framework provides competitive performance compared to strong baseline frameworks such as calibrated XGBoost, and improved recall and robustness for minority-class recurrence prediction. The results indicate that fusion learning improves sensitivity and framework stability, whereas calibrated XGBoost provides the strongest overall discrimination performance. The proposed framework presents a reliable, scalable, and clinically meaningful solution for individualized recurrence-risk prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.